Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
DCALNSE
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 9% | 7% | 8% |
| - | - | - | 2908% |
| - | -3% | 0% | -44% |
| 366% | 0% | 0% | 2% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
DCAL
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,849.9 | ₹447476 Cr | 37 | 12.07 | 62.82 | ₹11479 Cr |
| 9,602 | ₹254764 Cr | 87.1 | 34.04 | 128.41 | ₹2568 Cr |
| 4,928.5 | ₹189423 Cr | 86.85 | 16.72 | 97.06 | ₹2163 Cr |
| 1,180.3 | ₹116658 Cr | 25.85 | 9.42 | 62.53 | ₹5040 Cr |
| 1,399 | ₹111484 Cr | 33.08 | 9.77 | 57.87 | ₹3879 Cr |
| 2,026.2 | ₹109943 Cr | 100.55 | 6.8 | 29.25 | ₹889 Cr |
| 2,500 | ₹101712 Cr | 49.79 | 13.75 | 71.08 | ₹1913 Cr |
| 1,200.4 | ₹101005 Cr | 31.35 | 5.32 | 63.99 | ₹4196 Cr |
| 1,716 | ₹99253 Cr | 26.73 | 17.95 | 96.84 | ₹3505 Cr |
| 2,100.7 | ₹96031 Cr | 17.37 | 30.95 | 154.35 | ₹5333 Cr |
| 169.32 | ₹2719 Cr | 168.23 | -3.69 | 23.23 | ₹97 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
| ₹31 Cr | ₹31 Cr | ₹31 Cr | ₹31 Cr | ₹31 Cr | ₹31 Cr | ₹31 Cr | ₹32 Cr | ₹32 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹4810 Cr |
| ₹6646 Cr | ₹5800 Cr | ₹5596 Cr | ₹5778 Cr | ₹5518 Cr | ₹5667 Cr | ₹5684 Cr | ₹5347 Cr | ₹5075 Cr | ₹4 Cr |
| ₹6646 Cr | ₹5800 Cr | ₹5596 Cr | ₹5778 Cr | ₹5518 Cr | ₹5667 Cr | ₹5684 Cr | ₹5347 Cr | ₹5075 Cr | ₹4 Cr |
| ₹6677 Cr | ₹5832 Cr | ₹5628 Cr | ₹5810 Cr | ₹5549 Cr | ₹5699 Cr | ₹5715 Cr | ₹5379 Cr | ₹5107 Cr | ₹4814 Cr |
| ₹1535 Cr | ₹1129 Cr | ₹246 Cr | ₹1047 Cr | ₹762 Cr | ₹504 Cr | ₹222 Cr | ₹311 Cr | ₹386 Cr | ₹241 Cr |
| ₹0 | ₹20 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹19 Cr | ₹52 Cr | ₹139 Cr | ₹219 Cr |
| -₹71 Cr | -₹56 L | ₹29 Cr | ₹61 Cr | ₹125 Cr | ₹182 Cr | ₹138 Cr | ₹132 Cr | ₹125 Cr | ₹80 Cr |
| ₹955 Cr | ₹729 Cr | ₹735 Cr | ₹491 Cr | ₹501 Cr | ₹370 Cr | ₹236 Cr | ₹0 | ₹0 | ₹5 Cr |
| ₹428 Cr | ₹352 Cr | ₹379 Cr | ₹233 Cr | ₹277 Cr | ₹311 Cr | ₹294 Cr | ₹248 Cr | ₹234 Cr | ₹221 Cr |
| ₹2846 Cr | ₹2230 Cr | ₹1388 Cr | ₹1831 Cr | ₹1665 Cr | ₹1367 Cr | ₹909 Cr | ₹743 Cr | ₹884 Cr | ₹767 Cr |
| — | — | — | — | — | — | — | — | — | — |
| ₹211 Cr | ₹231 Cr | ₹244 Cr | ₹220 Cr | ₹193 Cr | ₹169 Cr | ₹284 Cr | ₹195 Cr | ₹186 Cr | ₹86 Cr |
| ₹1166 Cr | ₹993 Cr | ₹640 Cr | ₹842 Cr | ₹702 Cr | ₹559 Cr | ₹579 Cr | ₹430 Cr | ₹516 Cr | ₹457 Cr |
| ₹837 Cr | ₹655 Cr | ₹1620 Cr | ₹681 Cr | ₹493 Cr | ₹542 Cr | ₹688 Cr | ₹520 Cr | ₹393 Cr | ₹385 Cr |
| ₹103 Cr | ₹46 Cr | ₹51 Cr | ₹56 Cr | ₹31 Cr | ₹20 Cr | ₹18 Cr | ₹53 Cr | ₹83 Cr | ₹66 Cr |
| ₹2317 Cr | ₹1925 Cr | ₹2555 Cr | ₹1798 Cr | ₹1420 Cr | ₹1290 Cr | ₹1569 Cr | ₹1198 Cr | ₹1178 Cr | ₹994 Cr |
| ₹11840 Cr | ₹9986 Cr | ₹9571 Cr | ₹9439 Cr | ₹8634 Cr | ₹8356 Cr | ₹8193 Cr | ₹7321 Cr | ₹7169 Cr | ₹6574 Cr |
| ₹429 Cr | ₹423 Cr | ₹427 Cr | ₹443 Cr | ₹415 Cr | ₹394 Cr | ₹404 Cr | ₹355 Cr | ₹241 Cr | ₹222 Cr |
| ₹2775 Cr | ₹2084 Cr | ₹1964 Cr | ₹1825 Cr | ₹1421 Cr | ₹1166 Cr | ₹1056 Cr | ₹1042 Cr | ₹1095 Cr | ₹950 Cr |
| — | — | — | — | — | — | — | — | — | — |
| ₹12412 Cr | ₹10545 Cr | ₹10309 Cr | ₹9458 Cr | ₹8633 Cr | ₹8155 Cr | ₹7891 Cr | ₹6897 Cr | ₹6621 Cr | ₹6187 Cr |
| ₹4341 Cr | ₹3495 Cr | ₹3588 Cr | ₹3275 Cr | ₹2865 Cr | ₹2462 Cr | ₹2218 Cr | ₹1805 Cr | ₹1560 Cr | ₹1340 Cr |
| ₹8071 Cr | ₹7051 Cr | ₹6720 Cr | ₹6183 Cr | ₹5768 Cr | ₹5693 Cr | ₹5673 Cr | ₹5092 Cr | ₹5061 Cr | ₹4847 Cr |
| ₹275 Cr | ₹252 Cr | ₹501 Cr | ₹996 Cr | ₹755 Cr | ₹425 Cr | ₹202 Cr | ₹143 Cr | ₹119 Cr | ₹122 Cr |
| ₹75 Cr | ₹72 Cr | ₹79 Cr | ₹72 Cr | ₹32 Cr | ₹56 Cr | ₹84 Cr | ₹147 Cr | ₹101 Cr | ₹40 Cr |
| ₹75 Cr | ₹72 Cr | ₹79 Cr | ₹72 Cr | ₹32 Cr | ₹56 Cr | ₹84 Cr | ₹147 Cr | ₹101 Cr | ₹40 Cr |
| ₹275 Cr | ₹190 Cr | ₹193 Cr | ₹217 Cr | ₹211 Cr | ₹412 Cr | ₹413 Cr | ₹345 Cr | ₹299 Cr | ₹201 Cr |
| ₹2 Cr | ₹2 Cr | ₹66 L | ₹81 L | ₹66 L | ₹35 L | ₹5 Cr | ₹1 Cr | ₹6 Cr | ₹16 Cr |
| ₹8998 Cr | ₹7786 Cr | ₹7642 Cr | ₹7521 Cr | ₹6795 Cr | ₹6652 Cr | ₹6414 Cr | ₹5767 Cr | ₹5623 Cr | ₹5241 Cr |
| — | — | — | — | — | — | — | — | — | — |
| ₹16 Cr | ₹25 Cr | ₹23 Cr | ₹177 Cr | ₹293 Cr | ₹116 Cr | ₹107 Cr | ₹20 Cr | ₹94 Cr | ₹0 |
| ₹1019 Cr | ₹900 Cr | ₹883 Cr | ₹804 Cr | ₹645 Cr | ₹516 Cr | ₹581 Cr | ₹549 Cr | ₹485 Cr | ₹427 Cr |
| ₹673 Cr | ₹665 Cr | ₹484 Cr | ₹590 Cr | ₹473 Cr | ₹421 Cr | ₹577 Cr | ₹445 Cr | ₹444 Cr | ₹286 Cr |
| ₹991 Cr | ₹507 Cr | ₹413 Cr | ₹189 Cr | ₹172 Cr | ₹308 Cr | ₹161 Cr | ₹96 Cr | ₹69 Cr | ₹87 Cr |
| ₹32 Cr | ₹22 Cr | ₹45 Cr | ₹38 Cr | ₹66 Cr | ₹146 Cr | ₹76 Cr | ₹135 Cr | ₹81 Cr | ₹172 Cr |
| ₹110 Cr | ₹80 Cr | ₹79 Cr | ₹121 Cr | ₹189 Cr | ₹198 Cr | ₹277 Cr | ₹309 Cr | ₹373 Cr | ₹361 Cr |
| ₹2842 Cr | ₹2200 Cr | ₹1928 Cr | ₹1918 Cr | ₹1839 Cr | ₹1704 Cr | ₹1779 Cr | ₹1554 Cr | ₹1546 Cr | ₹1333 Cr |
| ₹525 Cr | ₹276 Cr | -₹627 Cr | ₹120 Cr | ₹419 Cr | ₹414 Cr | ₹210 Cr | ₹355 Cr | ₹368 Cr | ₹339 Cr |
| ₹11840 Cr | ₹9986 Cr | ₹9571 Cr | ₹9439 Cr | ₹8634 Cr | ₹8356 Cr | ₹8193 Cr | ₹7321 Cr | ₹7169 Cr | ₹6574 Cr |
| ₹426 | ₹372 | ₹359 | ₹371 | ₹354 | ₹363 | ₹364 | ₹333 | ₹316 | ₹0 |
| ₹426 | ₹372 | ₹359 | ₹371 | ₹354 | ₹363 | ₹364 | ₹333 | ₹316 | ₹0 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ₹105 Cr | ₹19 Cr | -₹122 Cr | -₹55 Cr | -₹4 Cr | -₹65 Cr | ₹197 Cr | ₹309 Cr | ₹231 Cr | ₹216 Cr |
| ₹436 Cr | ₹467 Cr | ₹377 Cr | ₹392 Cr | ₹325 Cr | ₹313 Cr | ₹330 Cr | ₹277 Cr | ₹235 Cr | ₹232 Cr |
| -₹45 Cr | -₹85 Cr | ₹144 Cr | -₹38 Cr | ₹90 Cr | ₹316 Cr | ₹132 Cr | -₹174 Cr | -₹206 Cr | -₹29 Cr |
| ₹496 Cr | ₹402 Cr | ₹398 Cr | ₹300 Cr | ₹411 Cr | ₹564 Cr | ₹660 Cr | ₹412 Cr | ₹260 Cr | ₹418 Cr |
| ₹491 Cr | ₹371 Cr | ₹379 Cr | ₹266 Cr | ₹355 Cr | ₹513 Cr | ₹585 Cr | ₹282 Cr | ₹226 Cr | ₹303 Cr |
| -₹245 Cr | -₹192 Cr | -₹230 Cr | -₹494 Cr | -₹619 Cr | -₹380 Cr | -₹442 Cr | -₹169 Cr | -₹297 Cr | -₹142 Cr |
| ₹201 Cr | -₹102 Cr | -₹22 Cr | ₹250 Cr | ₹130 Cr | -₹11 Cr | -₹98 Cr | -₹102 Cr | ₹78 Cr | -₹137 Cr |
| ₹447 Cr | ₹77 Cr | ₹128 Cr | ₹22 Cr | -₹133 Cr | ₹122 Cr | ₹46 Cr | ₹11 Cr | ₹7 Cr | ₹23 Cr |
| ₹341 Cr | ₹264 Cr | ₹132 Cr | ₹110 Cr | ₹244 Cr | ₹122 Cr | ₹76 Cr | ₹66 Cr | ₹59 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹35 Cr |
| ₹0 | ₹0 | ₹5 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹65 L |
| ₹788 Cr | ₹341 Cr | ₹264 Cr | ₹132 Cr | ₹110 Cr | ₹244 Cr | ₹122 Cr | ₹76 Cr | ₹66 Cr | ₹59 Cr |
Fundamental Ratios
Consolidated
Standalone
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 0
Bearish signals: 6 out of 9 oscillators
RSI
43.76Sell
STOCH %K
50.67Neutral
MACD Level(12,26)
-3.04Sell
Ultimate Oscillator
49.50Sell
Aroon Oscillator
-92.00Sell
BOP
-0.59Sell
CCI
-32.38Neutral
Williams %R
-49.33Neutral
Momentum
-8.80Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 1
Bearish signals: 8 out of 9 moving averages
EMA 9
169.35Sell
SMA 9
167.45Buy
EMA 21
171.63Sell
SMA 21
171.73Sell
EMA 50
176.65Sell
SMA 50
179.61Sell
EMA 200
192.78Sell
SMA 200
191.64Sell
WMA 20
169.59Sell
Pivot
Pivot
Classic
Resistance 5
192.23
Resistance 4
187.28
Resistance 3
182.33
Resistance 2
177.38
Resistance 1
175.36
Pivot
172.43
Support 1
170.41
Support 2
167.48
Support 3
162.53
Support 4
157.58
Support 5
152.63
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 59.32% | 59.32% | 59.32% | 59.32% | 59.32% | 59.32% |
| 6.86% | 7.45% | 7.66% | 8.07% | 9.94% | 9.49% |
| 0.64% | 0.56% | 0.18% | 0.28% | 0.19% | 0.19% |
| 1.41% | 1.06% | 1.08% | 1.08% | 1.07% | 1.06% |
| 31.77% | 31.61% | 31.76% | 31.25% | 29.48% | 29.94% |
Bulk & block deals
Name
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Crony Vyapar Pvt Ltd
Graviton Research Capital Llp
Graviton Research Capital Llp
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 11 Dec 2024 | Purchase | 33.38 Cr | ₹299.19 | 11.16 L | Bulk | 0.711572 | NSE |
| 11 Dec 2024 | Sell | 34.05 Cr | ₹299.90 | 11.35 L | Bulk | 0.724208 | NSE |
| 09 Dec 2024 | Purchase | 37.01 Cr | ₹277.86 | 13.32 L | Bulk | 0.849494 | NSE |
| 09 Dec 2024 | Sell | 31.59 Cr | ₹277.82 | 11.37 L | Bulk | 0.725189 | NSE |
| 05 Mar 2024 | Purchase | 24.05 Cr | ₹276.33 | 8.70 L | Bulk | 0.555206 | NSE |
| 05 Mar 2024 | Sell | 23.70 Cr | ₹276.77 | 8.56 L | Bulk | 0.546276 | NSE |
| 04 Mar 2024 | Purchase | 27.44 Cr | ₹267.80 | 10.25 L | Bulk | 0.653453 | NSE |
| 04 Mar 2024 | Sell | 23.28 Cr | ₹268.49 | 8.67 L | Bulk | 0.553055 | NSE |
| 28 Dec 2023 | Purchase | 16.02 Cr | ₹173.12 | 9.25 L | Bulk | 0.590287 | NSE |
| 28 Dec 2023 | Sell | 16.02 Cr | ₹173.06 | 9.25 L | Bulk | 0.590287 | NSE |
Insider trading & SAST
Client name
Aditi J Vyas & Mansi J Vyas
Param Value Investments
Nikunj Desai
Nikunj Desai
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 08 May 2024 | Promoter | Acquisition | 11.86 | — | 0 | — | 1.86 Cr | 01 Jan 1900 | — | — | SAST | 10(5) | — |
| 13 Jul 2023 | Other | Acquisition | 0.96 | 5.23 | 0 | — | 15 L | 20 Jun 2023 | Market | 82,00,000 | SAST | 29(1) | — |
| 16 Feb 2023 | Immediate Relative | Acquisition | 0.000353 | 0.01 | 55.34 K | ₹99.90 | 554 | 15 Feb 2023 | Market Purchase | 13,500 | Insider Trading | — | Equity Shares |
| 16 Feb 2023 | Immediate Relative | Acquisition | 0.003654 | 0.01 | 5.71 L | ₹99.75 | 5.73 K | 13 Feb 2023 | Market Purchase | 12,946 | Insider Trading | — | Equity Shares |
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Dishman Carbogen Amcis Limited (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with
Corporate Actions
Date
Type
Details
Company details
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Dishman Carbogen Amcis Share Price
168.19-5.14 (-2.97%)
-45.21% past 1 Year
News
Dishman Carbogen subsidiary clears first US FDA audit at Swiss plant
Equity
DCAL
Dishman Carbogen Amcis subsidiary clears first US FDA inspection, no observations
Equity
DCAL
Dishman Carbogen Q4 EBITDA rises YoY but margin contracts on lower profitability
Equity
DCAL
Dishman Carbogen Q4 revenue grows strongly year-on-year to Rs 851 crores
Equity
DCAL
Dishman Carbogen reports lower quarterly net profit in latest result
Equity
DCAL
Dishman Carbogen Amcis Subsidiary Carbogen Amcis B.V. Secures GMP Compliance Certificate for Veenendaal Facility.
Equity
DCAL
Dishman Carbogen Amcis Q3 FY26 EBITDA Decline: YoY Margin Contraction
Equity
DCAL
Dishman Carbogen Amcis Reports Q3 Net Loss of Rs 13 Crores vs YoY Profit.
Equity
DCAL
Dishman Carbogen Amcis board clears Rs 50 crores secured NCD issue at 10 percent
Equity
DCAL
Dishman Carbogen Amcis Board Meeting on Dec 27 to Discuss NCD Funding Proposal.
Equity
DCAL
Dishman Carbogen Amcis subsidiary secures expanded Swiss credit capacity through refinancing initiative.
Equity
DCAL
Dishman Carbogen Amcis Q2 FY26: Net profit rises sharply as revenue falls; operating margin expands
Equity
DCAL
Dishman Carbogen Amcis merges Carbogen Amcis Specialities AG and Carbogen Amcis Innovations AG
Equity
DCAL
Dishman Carbogen Amcis announces partnership with Celonic Group for ADC platform development
Equity
DCAL
Dishman Carbogen Amcis rises on receiving EIR from USFDA
Equity
DCAL
Dishman Carbogen Amcis receives EIR from USFDA
Equity
DCAL
Dishman Carbogen Amcis: Company Gets Eir From Us Fda Confirming Inspection Closure. ??
Equity
DCAL
Dishman Carbogen Amcis: Co Is Expanding Complex Api Capabilities, Deepening Cdmo Partnerships, And Leveraging Regulatory Clearances In The U.S. & Eu To Tap High-Value Pharma Outsourcing Demand
Equity
DCAL
Dishman Carbogen Amcis: Q1 Ebitda 140.00 Crores Rupees Vs 30.00 Crores (Yoy) || Q1 Ebitda Margin 19.82% Vs 5.73% (Yoy)
Equity
DCAL
Dishman Carbogen Amcis: Q1 Cons Net Profit 23.40 Crores Rupees Vs Loss 77.60 Crores (Yoy) || Q1 Revenue 708.00 Crores Rupees Vs 523.00 Crores (Yoy)
Equity
DCAL